Article, News
Prescient Therapeutics “an ASX-listed oncology drug developer with a big FY25 ahead”, says Pitt Street Research
A strong and diversified pipeline has led Pitt Street Research to value Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) at up to 16.4 cents per share, using a Sum…
Article, News
Prescient Therapeutics: PTX-100 Phase 2 coming soon
Prescient Therapeutics update report 2024 08 29
Article, Media, News
Prescient Therapeutics PTX-100 shows promising results in Phase 1b study
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) CEO and managing director Steven Yatomi-Clarke sits down with Jonathan Jackson in the Proactive studio ahead of a presentation of the…
Article, News
Prescient Therapeutics to present PTX-100 results at T-Cell Lymphoma Forum in California
Clinical-stage oncology company Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) has been invited to present PTX-100 Phase 1b results at the 15th Annual T-Cell Lymphoma Forum (TCLF) to be…
Article, News
Prescient Therapeutics to present PTX-100 results at 5th World Congress of Cutaneous Lymphomas
Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) will present results of its Phase 1b study of PTX-100 in T-cell lymphomas during a poster presentation at the 5th World Congress…
Article, Media, News
Prescient Therapeutics on cusp of value creation, says Pitt Street Research
In valuing Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) at A11.6 cents per share in its base case and A16.3 cents in its bull case, Pitt Street Research said the ASX-listed…
Article, Media, News
Prescient Therapeutics (ASX: PTX) advances PTX-100 to pivotal Phase 2 study
PTX-100 of Prescient Therapeutics Limited (ASX: PTX) is in spotlight as it is entering a new stage. The company highlighted that PTX is on the…
Article, News
Prescient Therapeutics secures speculative buy recommendation from Bioshares
Bioshares has a Speculative Buy Class B recommendation for Prescient Therapeutics Ltd (ASX:PTX, OTC:PSTTF) after the company released positive trial results from its Phase Ib study in…
Article, News
Prescient to advance PTX-100 to phase II for refractory T-cell lymphomas
Clinical-stage oncology company Prescient Therapeutics (ASX:PTX) has announced the results of its Phase 1b study of PTX-100 in patients with advanced malignancies. The study’s focus…
Article, News
Prescient Reveals PTX-100 Phase 1b Study Results in T-Cell Lymphoma
Clinical-stage oncology company Prescient Therapeutics (ASX:PTX) has announced the results of its Phase 1b study of PTX-100 in patients with advanced malignancies. The study’s focus…